This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
The Structure Therapeutics (NASDAQ:GPCR) stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential.What Happened: JPMorgan
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.07% on an annualized basis producing an average annual return of 11.12%. Currently, Gilead Sciences has a market c
Shockwave Medical Gains After HSR Waiting Period for Sale to J&J Expires
JPM Lists Stocks With the Least Price Swings, Most Attractive Option-sale Candidates
Hospira Inc. Issues A Voluntary Nationwide Recall For Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection, USP Carpuject Units Due To The Potential For Incomplete Crimp Seals - Press Release
Hospira Inc. Issues A Voluntary Nationwide Recall For Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection, USP Carpuject Units Due To The Potential For Incomple
Smart Money Is Betting Big In JNJ Options
Deep-pocketed investors have adopted a bullish approach towards Johnson & Johnson (NYSE:JNJ), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unv